How to use the Avamys device
Watch the video to find out more.
Patient preference study
In a multicenter, randomized, double-blind, cross-over, patient preference study, that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis, 56% of patients preferred Avamys over MFNS (32%) 3 (n=300, p<0,001). The patient preferences of products may contribute to improved treatment adherence and enhanced treatment outcome in AR patients. 4
Overall 5 patients (2%) reported AEs with FFNS and 13 patients (4%) with MFNS. Few common AEs were reported: rhinorrhoea, nasal discomfort, cough. No severe safety issues were identified during the study. 3
AE: Adverse event; AR: Allergic rhinitis; FFNS: Fluticasone furoate nasal spray; MFNS: Mometasone furoate nasal spray.
- Avamys summary of product characteristics.
- Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv. 2007;4(6):689-701.
- Yanez A, Dimitroff A, Bremner P, et al. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol. 2016;7(4):e183–e192.
- Yonezaki M, Akiyama K, Karaki M, et al. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx. 2016;43(3):292-297.